Genotype 3/Improvement reported in hepatitis-C treatment rate

[Guest guest]

Genotype 3/Improvement reported in hepatitis-C treatment rate

Improvement reported in hepatitis-C treatment rateISLAMABAD, Apr 14 (APP): Pakistani doctors will present a new research on hepatitis-C treatment in five-day 45th European Association of Study of Liver diseases (EASL) meeting commenced on Wednesday in Vienna, Austria. The researchers found that 90% patients stayed free of virus after one year completion of treatment which was a very important development and provides a roadmap for treatment policy.This treatment plan suggested in the study will decrease the chances of recurrence of disease in condition when country’s people are facing a challenge of poor choice of injection and inappropriate duration of treatment of hepatitis C.The study was conducted by young researchers Dr Uzma Adeeb and Dr Fatima Khattak, under the supervision of Professor Muzzaffar Gill.

http://www.app.com.pk/en_/index.php?option=com_content & task=view & id=100679 & Itemid=2

The study was conducted on Pakistani patients with hepatitis C (genotype-3) with objective to assess the viral responses and their impact on treatment duration of those patients who were HCV PCR negative after four weeks of treatment of Pegylated Interferon plus Ribavirin.The study suggested that the patients who become HCVPCR negative after 12 injections will need at least nine to 12 months of therapy.Chronic Hepatitis C treatment is a rapidly changing arena and there are rapidly changing guidelines about the type of interferon use and duration of treatment.The research said that there are new tools and parameters which both patient and doctors who treat these patients, need to understand.Viral kinetics has gain more importance in year 2010 which helps to find out, how the hepatitis-C virus and human body responds to introduction of Pegylated interferon.If patient becomes HCVPCR negative

after four Pegylated interferon injections, the chances are very high that particular individual will remain free of disease after completion of the treatment.

http://Hepatitis Cnewdrugs.blogspot.com/2010/04/improvement-reported-in-hepatitis-c.html